Cipla says govt seeks $86 m for drug over-pricing

The demands are contrary to the orders passed by the Supreme Court of India and are related to the same drugs under litigation, the drugmaker said in a statement.

The company has received a legal advice which says the entire amount demanded by the National Pharmaceutical Pricing Authority (NPPA) is not tenable and sustainable, Cipla said.

NPPA is a government body that fines drugmakers in India if they over price certain drugs that have been identified under the national list of essential medicines.